Is Body Language That Important During Face-to-Face Job Interviews and Business Meetings?

If you would have asked me that question before I became a professional recruiter and hiring manager, I would have suggested that body language plays a minimal role in the success or failure of a face-to-face job interview or business meeting. However, over the years, I have come to realize that body language is extremely important; and it may be the deciding factor in whether or not a job offer is proffered or a business deal is consummated.

To that end, Celina Jacobsen from the Career Overview Blog sent me a link to one of their posts. While much of the post wasn’t germane to life sciences career development, parts of it were spot on with regard to the importance of body language during job interviews and business meetings. With this in mind, I reproduced parts of the post that I think would be useful to BioJobBlog readers for career development insights.

Body Language and the Job Interview

Pay attention to your body language using these tips to ensure you are giving the best impression during a job interview.

  1. Handshake. Everyone knows that a handshake is an important element of first impressions. Offer a firm handshake that shows confidence in yourself.
  2. Don’t cross arms and legs. Crossing your arms or legs is seen as a defensive position and is not what you want to present to your prospective employer.
  3. Sit or stand with legs slightly apart. When you sit or stand with your legs slightly apart, this gives the impression that you are self-confident.
  4. Keep your hands and legs still. Fidgeting exudes nervousness. Instead, keep your hands relaxed in your lap and be aware of what your legs are doing.
  5. Chair movement. If you are sitting in a chair that swivels, be sure you aren’t accidentally turning back and forth as it can be distracting and also makes you appear nervous.
  6. Voice tone. Be aware of your voice tone qualities. Don’t be monotonous, yet don’t let your voice tone vary to such extremes that you sound excited or nervous. One helpful tip is to take a deep breath before speaking.
  7. Be aware of the interviewer’s body language. Pay attention to what the person interviewing you is saying through her body language. Not only can you determine if she is interested in what you have to offer, you can also match your body language to the level of formality.
  8. Palms up. Use hand gestures that keep your palms up, which indicate you are open and friendly. Gestures with palms down tell the interviewer that you may be dominant or aggressive.
  9. Keep eyes focused. Shifty eyes moving all around the room will give your prospective employer the feeling that you are being dishonest, or at best, uncomfortable.
  10. Active listening. Be an active listener during the interview. Make eye contact, nod your head while others are speaking, and interject a few verbal acknowledgements such as "yes" or "I see."

Body Language in Business and Career Development

What you say with your body language can convey as much to your business colleagues as your words. Learn how to manage your body language in a business setting to help promote your career.

  1. Relax your shoulders. When many people feel tension, they pull up their shoulders. Be conscious of this and relax your shoulders. Not only will this help prevent neck and back pain, it makes you appear less stressed, too.
  2. Be mindful of your head position. Holding your head level both vertically and horizontally indicates confidence and asks others to take you seriously. If you want to show that you are listening and open to the other person, tilt your head slightly to one side.
  3. Use your hands. Hanging your hands down by your side during a presentation indicates depression. Instead, keep your hands active and use gestures to show involvement and energy.
  4. Remove the opportunity for eye contact in conflict. If negotiations have turned sour or co-workers are disagreeing, moving them to a different form of communication that does not involve eye contact, such as email or IM, may diffuse the situation and allow for a better flow of communication.
  5. Keep your hands out of your pockets. Standing with your hands in your pockets may send several signals to those around you, probably none of them what you intend. Unless you are trying to look less confident, as if you are holding yourself back, you are bored, or you are hiding something, then take your hands out of your pockets.
  6. Women, learn the "business gaze". For women, a key element to being taken seriously is the "business gaze" or holding your line of sight on the area from the eyes to the mid-forehead. A gaze held lower indicates a more "social gaze."
  7. Make eye contact with everyone. If you are in a meeting or giving a presentation, make it a point to make eye contact with each one of the people involved (unless it’s a packed house and physically impossible to do).
  8. Watch your stance. Standing in a commando stance, with legs spread and hands on hips, tells others you are feeling disapproving, superior or are arrogant.
  9. Keep your hands from behind your head. Sitting back with your hands clasped behind your head is another position that communicates arrogance or superiority.
  10. Interruptions. If you are in the middle of a conversation with a superior or in a meeting that has been interrupted, it is best to look away from the person dealing with the interruption in an effort to give them privacy and to indicate you have disengaged yourself from something that is not your business.

I hope that you found these tips useful and apply them to your next job interview or business meetings.

Hat tip to CareerOverview.com

Until next time…

Good Luck and Good Job Hunting!!!!!!!!!

 

Looking for a Life Sciences Internship? Internships.com May Help

A common lament from that I frequently hear from graduate students and postdoctoral scientists  at career development meetings is the need for "prior industry experience" to qualify and be considered for an industrial science job. Invariably, someone asks: “How in the world am I supposed to get industrial experience if nobody is willing to hire me as an industrial scientist?” Prior to the financial meltdown, I frequently advised PhD-trained scientists seeking industrial jobs to consider positions in smaller, local biotechnology companies.

While the pay, visibility and status is likely to be less than that of employees at major pharmaceutical or biotechnology companies, spending a year or more at a smaller company still qualifies as industrial experience. This, in turn, opens the door for new opportunities at larger, more established life sciences companies; which tend to offer more career options for industrial scientists. However, over the past three years or so, over 200,000 pharmaceutical employees have lost their jobs and many biotechnology companies are on the verge of bankruptcy. Consequently, entry level positions at smaller local biotechnology companies are gradually disappearing as job possibilities for newly-minted graduate students and postdoctoral fellows.

Interestingly, the financial crisis and high unemployment rates have elevated the once lowly corporate internship to “must have status” for job seekers who are interested in landing entry level positions at many life sciences companies.  While corporate life sciences internships are in high demand, they are typically not well publicized and frequently limited to students enrolled in certificate and degree programs. Put simply, corporate life sciences internships for graduate students and postdoctoral fellows, which are in high demand, are extremely difficult to find!

For the past several years, I wanted to create a website devoted to internship opportunities for life sciences graduate students and postdoctoral fellows. To that end, I approached several life sciences search engine companies and a couple of placement firms but was unable to convince them of the value and need for such as site. About a week ago, I came across a website called Internships.com that is exclusively devoted to “all things internship.” While the site is still in beta and the number of life sciences internship opportunities is limited, I think that it has enormous potential for graduate students and postdoctoral scientists who may be seeking industrial internship opportunities.

In the spirit of transparency and full disclosure, I have no relationship, financial or otherwise, with Internships.com. I just think it is a great idea and hope that the folks behind Internships.com are successful!

Until next time…

Good Luck and Good Internship Hunting!!!!!!!!

 

Resumes, Curriculum Vita and Cover Letters

After almost a week advising students about the difference between resumes and curriculum vita (for scientists there is no difference), academic vs. an industrial curricula vitae and cover letters at Experimental Biology this year, I came to two conclusions. First, all scientists should take a resume writing course. Second, there is no single resource to help students and postdocs figure out a way to navigate the sometimes treacherous waters of resume writing and cover letters.

Much to my surprise and delight, Monica Kerr, who is Director of Science Alliances at the New York Academy of Sciences, offered a link to a great resource developed by Harvard’s Office of Career Development. The document entitled “CVs and Cover Letters” offers ideas and samples of academic CVs and cover letters. Further, it provides insights into formatting and verb usage when constructing CVs and resumes. While the document does not address how to construct an industrial CV, it is one of the best resources that I know of for resume writing for life scientists.

Those of you looking who may be looking for advice and guidance about constructing industrial strength CVs can check out a post that I crafted for BioJobBlog a couple of years ago. Like the Harvard document it focuses on CV formats, verb usage and other job search related items.

Hat tip to Monica (and Harvard Office of Career Development)!

Until next time…

Good Luck and Good Job Hunting!!!!!!!!!!!

 

Scientist Comedian Tim Lee Returns to NYC

Tim Lee a PhD-trained scientist who left the lab behind to try his hand as a stand-up comedian returns to the comedy club The Monkey (37 West 26th Street, New York City, NY) on May 9, 2010. Tim's unique comedy show, that blends stand up comedy with science and humorous PowerPoint presentations, received rave reviews in the New York Times the last time he was in NY.

Tim has become a bit of an internet sensation of late with over 3 million views of his YouTube videos. His show at The Monkey will be on 

Sunday May 9th at 8PM at The Monkey,
Tickets: http://www.brownpapertickets.com/event/106489 

If you are interested in attending, please contact me. I have some free tickets!

Until next time...

Good Luck and Good Job Hunting

The Dog Grifters: Donna Roberts and Dawn Abrams Strike Again

Despite a down economy, it appears that business for the dog grifting team of Donna Roberts aka Marcie Duben (and many other false identities) and Dawn Abrams is booming. The reason that  I know this is that over the past week or so I have received several message regarding from BioJobBlog readers about bogus dog transactions.
 
The interesting thing about these despicable human beings is that they seem to think that they can continue ;to get away with ripping people off with no reprecussions. The reason I continue to post stories about them is the hope that more and more people will learn about them and eventually we will; be able to shut down their fradulent puppy mill ring!  To that end, please pass the information along that nobody ought to buy dogs from these grifters! 
 
Hopefully, if enough us band together and remain vigilant in spreading the word about these nefarious individuals then we will prevail and doglovers will be able to sleep better at night.
 
Unitl next time...
 
Good Luck and Spread the Word about Donna and Dawn

 

 

Five Hot Alternate Career Opportunities for Life Sciences PhDs

While attendance may be down at this year's Experimental Biology meeting in Anaheim CA aka the city that Disney built, attendance at FASEB Career Development seminars has been greater than normal. This is not surprising given the state of the economy and the increased competition for traditional career opportunities for persons with a life sciences PhD degree which include academic and pharmaceutical R&D jobs. With this in mind, I thought it might be useful to list some of the fastest growing and hottest new alternate career job opportunities for PhD life scientists. 

  1. Health informatics technologists (HIT)
  2. Medical writers (especially those with experience in regulatory affairs)
  3. Clinical trials personnel (especially biostatisticians and operations professionals)
  4. Management consultants with backgrounds in health care outcomes and economics
  5. Biomanufacturing scientists (especially quality control and assurance specialists)

 In future posts, I will discuss the qualifications and activities associated with each of these job opportunities

 Until next time... 

Good Luck and Good Job Hunting!!!!!

 

The Job Hunt: Tips from a Hiring Manager

As a career development professional, I frequently offer job seekers tips on how to conduct a successful job search. However, my views on the topic are mainly derived from a five year stint as a professional recruiter and over 20 years as a job seeker. With this in mind, it may helpful for job candidates to hear the other side of the story; that is, what hiring managers expect from job seekers.

To that end, I found a great podcast (created by an HR professional) that briefly but cogently outlines a hiring manager’s views and expectations of job seekers who are applying and interviewing for positions at her company. 

If you want to learn more about job searches, the interviewing process and other job-related topics, I highly recommend that you visit the Secrets of the Job Hunt website. It contains hundreds of podcasts, videos and other information on a plethora of imaginative, career development topics.

Until next time…

Good Luck and Good Job Hunting!!!!!!!   

 

Experimental Biology 2010: Anaheim

I will be at the Experimental Biology meeting this year in Anaheim from April 22-27 doing my annual career development presentations and resume critiquing. Also, this year, I am bring my Flip camera this year to video interesting scientists, students and others who want to be featured in the Career Corner at BioCrowd.

In case you were wondering the titles of this year’s career development seminars include:

  1. Alternate Careers: Taking the Road Less Traveled
  2. Interviewing Tips and Insights
  3. How to Use Social Media to Find Gainful Employment in the Life Sciences Industry
  4. Career Opportunities in the Life Sciences Industry

Please feel free to drop in to listen to one of my talks or sign up for a resume critiquing session.

See you in Disney Land…oops I mean Anaheim!

Until next time…

Good Luck and Good Job Hunting!!!!

 

National DNA Day 2010

National DNA Day is a unique day when students, teachers and the public can learn more about genetics and genomics! The day commemorates the completion of the Human Genome Project in April 2003, and the discovery of DNA's double helix.

The annual event started seven years ago is sponsored by the National Human Genome Research Institute of the National Institutes of Health. To learn more about the activities that are planned for this year's celebration, please click here.  And this year, you can become a fan of the day on Facebook!

Have a great day celebrating, but please remember to clone responsibly!!!!!!

Until next time...

Good Luck and Good Sequencing!!!!!!!!!!

Genzyme Expected to Be Fined Almost $200 Million for Manufacturing Problems

Genzyme announced yesterday that it expects to be fined roughly $175 million in fines and penalties related to the manufacturing troubles at its Allston Landing, MA manufacturing plant that resulted in severe shortages of two of its best selling products, Cerezyme (Gaucher disease) and Fabrazyme (Fabry disease) 

The fines and penalties are part of a consent decree that the US Food and Drug Administration (FDA) intends to levy against the company for the manufacturing infractions. A substantial portion of the penalties included a disgorgement settlement, a process that allows FDA to collect a certain percentage of the sales of products made at the troubled Genzyme production facility.

According to an article in today’s New York Times business section, Genzyme representatives said that patients using Cerezyme would continue getting half a dose for two or three more months. It previously said full supplies would be restored May.

Patients who use Fabrazyme would continue to be allocated a third of their usual dose at least through the third quarter. The company had previously hoped to resolve the Fabrazyme shortage in the third quarter.

The highly publicized manufacturing problems at Genzyme, has shaken both physician and patient confidence in the company’s ability to safely manufacture and supply sufficient quantities of Cerezyme and Fabrazyme; two orphan drugs designed to treat patients with debilitating genetically-inherited diseases. 

Several physicians and patients who were previously loyal and ardent supporters of Genzyme, have indicated that they may switch to recently approved and new treatments being developed by Genzyme’s competitors that include Shire.

The lack of commitment to quality manufacturing by Genzyme executives has seriously tarnished the image of a once highly respected and reputable orphan drug developer.

Until next time…

Good Luck and Good Job Hunting!!!!!

Until next time…

Good Luck and Good Job Hunting!!!!!!!   

 

Social Communications and Healthcare Meeting: Act II

Last July, I attended the Business Development Institute’s (BDI) first conference on Social Communication and Healthcare that was held in NYC. The meeting was outstanding and was a great introduction to many of the exciting things that are currently going on with social media and the life sciences. Also, I was able to meet and network with some of major players and companies leading the charge in social communications and healthcare.

The success of the first meeting induced BDI organizers Steve Etzler and Maria Feola to schedule the 2nd annual Social Communications & Healthcare – Case Studies and Roundtables that will be held on May 11, 2010 from 8:30AM to 1:00 PM at The Graduate Center of The City University of New York in midtown Manhattan, New York City

 The agenda will consist of several case study presentations in the general auditorium with 350+ attendees. The presentations will be followed by two moderated interactive roundtable discussion group sessions with 8-12 attendees each on very specific topics. We will also host a networking breakfast and networking breaks between sessions.

Topics to be discussed include:

  • Regulatory and legal issues when planning and implementing social media strategies
  • Connecting with consumers who already using the internet for healthcare information
  • Case studies of leading brands that use internet-based social strategies to achieve communications objectives?
  • Examples of social communities that demonstrate how leading healthcare brands interact, educate, and provide value to consumers online
  • Why real-time social media tools such as Twitter are gaining momentum and how to use them
  • The impact of social media on “crisis communications “in the healthcare industry?
  • Selling social communications projects and proving ROI to senior management?
  • How to create effective partnerships with new healthcare media leaders beyond advertising
  • Examples of how to use social communications to connect internally with employees and stakeholders?
  • What are the some of the tools, technologies, and best practices for monitoring and measuring social communications
  • Updates on impending FDA guidelines for the use of social media in the life sciences industry

Some of the speakers and moderators who will be attending are:

  1. Ann Aiken, Health Communications Specialist, Center for Disease Control (CDC)
  2. Jarvis Cromwell, Managing Principal, Reputation Garage
  3. Zoë Dunn, Principal, Zoë Digital Consulting
  4. Robert Halper, Director of Video Communication, Johnson & Johnson
  5. Lance Hill, CEO, Within3
  6. Brian Kaufman, Senior Director Client Solutions, KIT digital, Inc.
  7. Ira Kaufman, Integrated Marketing Strategist, Entwine Inc.
  8. Ray Kerins, Vice President / Worldwide Communications, Pfizer Inc.
  9. Alan Levy, CEO, BlogTalkRadio
  10. Cliff Mintz, Co-Founder, BioCrowd
  11. Marc Monseau, Director, Corporate Communications & Social Media, Johnson & Johnson
  12. Mario Nacinovich, Editor-in-Chief, Journal of Communication in Healthcare
  13. Ellen Resnick, Founder,Resnick Consulting & Vice President, Membership,IABC- NJ
  14. Jonathan Richman, Director of Strategic Planning, Bridge Worldwide & Author, Dose of Digital
  15. Alex Romanovich, Founder, Chief Marketing Officer, Social2B
  16. Nancy Shenker, Founder & CEO, theONswitch
  17. Brian Simpson, Assistant Director Food & Beverage and Social Hospitality, The Roger Smith Hotel
  18. Bill Sobel, Chief Connections Officer, SobelMedia LLC
  19. Alicia Staley, The Staley Foundation
  20. Patsy Stewart, Director Social Media Marketing & Training, Entwine Inc.
  21. Steve Woodruff, Founder and President, Impactiviti

A partial list of companies and organziations that will be attending include Pfizer, Johnson & Johnson, Bayer Healthcare, AstraZeneca, Centers for Disease Control, the Robert Wood Johnson Foundation, Forrest Laboratories, Digitas Health, BlogTalk Radio, PR Newsire, Boston University and many others.

For more information, including registration, please click here to visit the event website. Or contact Steve Etzler at setzler@bdionline.com or 212-765-8045.

BioJobBlog readers can use promo code BC for a discounted rate of $155.

I hope to see you at the meeting!!!!

Until next time …

Good Luck and Good Tweeting!!!!!!

 

Getting a PhD Degree: The Long Slog

Often times, people ask me why I decided to get a PhD degree. They mostly ask because they find it difficult to fathom why a person would choose to go to school for such a long time to obtain a degree that doesn't guarantee a job upon completion.  I have long contended that passion, not employment, is the main driver in the decision to get a PhD--but I digress.

Back in ancient times when I started graduate school, the average time it took to attain a PhD degree in my department (Bacteriology, University of Wisconsin-Madison) was about 5.5 years (this included a mandatory Masters degree). At the time, many faculty members thought that the average time to a PhD degree was too long. Consequently, they instituted an ambitious plan and mandate to reduce the time to a PhD from 5.5 to 4.0 years.  Interestingly, only one person in our class of 25 was able the complete a PhD degree in 4.0 years (he got very lucky). The time it took for the rest of us (who remained in the PhD degree program) ranged from 5.0 to 10 years. 

With this in mind, the New York Times published an article in its Education Life supplement last weekend that compared the average length of time it takes to attain a PhD in various disciplines; ranging from the life sciences to the humanities.

While it should come as no surprise that it takes longer to obtain a PhD degree in humanities as compared with other disciplines, the average length of time that it takes to get a PhD in the life sciences has ballooned to almost 7 years! 

I am certain that this increase reflects the lack of urgency to finish a PhD in the life sciences because of the growing shortages of jobs in the sector. However, I believe that keeping students in graduate school for inordinately long periods of time doesn’t do them much good with regard to long term career outcomes. This is because —as most card- carrying PhDs will tell you—the real education doesn’t truly begin until your first postdoctoral fellowship or full time job.

While graduate school may seem extremely difficult and overwhelming at times, it truly doesn’t compare with the pressures, demands and anxieties pervasive in the working world. To that end, shortening the time PhD students spend in graduate school may afford them the opportunity to begin to experience the “real world” prior to the age of 35 to 40; the current age range of most life sciences PhDs looking for the “their first real jobs.”

Alternatively, if the time it takes to obtain a life sciences PhD degree can not be shortened, then it would behoove graduate programs to begin to integrate specialized instructional programs, e.g. alternate careers, career counseling, resume writing and interviewing workshops, etc, into their  curricula to more adequately prepare students for the working world.

Until next time…

Good Luck and Good Job Hunting!!!!!!!!!!

 

The Reality of Grade Inflation

For the past 10 years or more I have listened to complaints about grade inflation at both the high school and college levels. Until now, these complaints were largely anecdotal and consequently their validity, while probably correct, was unsubstantiated. It turns out, as reported in an article entitled “A as the New B” in this past weekend’s New York Times Education Life section, that college grade inflation is alive and well (see below)

Back in the day, grades were generally distributed along a “normal curve” which meant that the majority of grades were in the middle of the curve (average) and the below and above average grades were found at the left and right tails of the curve respectively. A cursory review of the data presented in the table above indicates that grades are disproportionately skewed to the right making “Bs” the new C and “As” the new B. For example, I knew that Brown University was a great school but do 67% of the students who take classes there really deserve A grades? After all, conventional wisdom suggests that even among a group of geniuses their talents and abilities ought to be distributed along a normal curve.

While “As” look great on college transcripts, it no longer means that students who have obtained these grades have excelled or mastered the subject material offered in certain courses. With this in mind, how is an employer going to be able to evaluate prospective job candidates? 

Until next time…

Good Luck and Good Studying!!!!!!

 

Why I Love Wisconsin

Yesterday, a bill to designate Lactococcus lactis (formerly Streptococcus lactis) the official state microbe passed the Wisconsin assembly and now awaits action in the state senate. L. lactis is the bacterium used to make cheese, and as many of you know Wisconsin makes a lot of cheese.

As many of you may know, I received my PhD in Bacteriology from the University of Wisconsin-Madison and it was Ken Todar, my former mentor, friend and teacher extraordinaire (now emeritus) in the department who originally lobbied the state legislature to consider selecting L. lactis as the state microbe.

The bacterium is poised to join the state’s list of 21 designated symbols, which includes an official dance (the polka), beverage (milk) and domesticated animal (the Holstein dairy cow).

To learn more about L. lactis and its possible ascendancy as the first ever state microbe designation, listen to a podcast of an interview with Elio Schaechter, PhD, former longtime Chair of the Department of Microbiology at Tufts University, past President of the American Society for Microbiology and science education advocate.

Finally, I will be back in Madison next month to attend a meeting where my mentor, Bob Deibel (now 86 or so), will receive a lifetime achievement award for his work in food microbiology. This will be my first visit back to UW since the mid 90s. I am especially looking forward to eating a brat and drinking a few steins of Leinnies on terrace! Maybe I will be lifting a few to toast L. lactis as well!

Until next time…

Good Luck and Good Job Hunting!!!!!!

 

One Biopharmaceutical Company's Loss is Another's Gain

The recent manufacturing woes of orphan drug manufacturer Genzyme have been well documented and widely publicized. These problems resulted in massive shortages of some of its top selling drugs Cerezyme (Gaucher disease) and Fabrazyme (Fabry disease) causing many of the patients who depend on these drugs to maintain their quality of life to go without reduced or no treatments for months. 

Because both drugs were approved by the US Food and Drug Administration (FDA) as orphan drugs they enjoy seven years of market exclusivity from the date of regulatory approval which prohibits other companies from seeking approval and selling similar drugs in the US. Consequently, Genzyme is the only commercially-available source for the drugs. Genzyme’s ongoing biomanufacturing created massive shortages of both drugs last summer. Because of this, FDA allowed two other companies, Shire and Protolix Biotherapeutics (both have treatments for Gaucher (Protalix) and Fabry (Shire) disease in late stage clinical development), to make their drugs available (at no charge) to patients prior to regulatory approval. This was a relatively rare and bold move by the agency. But, to be fair, they had little choice because so many patients were suffering.  

In case you may be wondering there are approximately 1500 Cerezyme users and fewer than 1000 Fabrazyme users in the US. Despite the small numbers of patients, the cost of the treatments are extraordinarily high; costing patients as much as $200,000 per year for treatment.

According to an article in today’s NY Times as many a 15 percent of American Cerezyme users have switched to a different drug. Fewer patients with Fabry disease have switched mostly because Shire’s drug for Fabry disease Replagal was less widely available. The almost year-long shortages of both drugs have seriously tarnished Genzyme’s reputation. And previously loyal patients are questioning their almost decade long allegiance to the company. This, coupled with a 26 per cent decline in Genzyme’s stock price last year suggest that Genzyme’s standing as one of the top five biotechnology companies in the world may be in serious jeopardy. 

Despite calls for his resignation (and an attempt by Carl Icahn to wrest control of the company), CEO Henri A. Termeer, who has led Genzyme for over 20 years has vowed not to resign. While manufacturing problems are not uncommon in the biotechnology industry, the severity and ongoing nature of the manufacturing problems at Genzyme’s Allston Landing, MA production facility are unacceptable; especially for a company that specializes and prides itself in developing treatment for orphan disease indications. The FDA recently announced that it would fine Genzyme and place its manufacturing operations under a consent degree for an indefinite period of time.

Genzyme representatives now contend full supplies of Cerezyme will be available after May 1 and those for Fabrazyme possible in the third quarter of this year.

While so-called “copycat” or “me too” drugs developed by pharmaceutical companies tend to be vilified by consumers and patient advocacy groups, the agency prefers to approve more than one treatment option for a given disease indication in case one medication doesn’t deliver the intended therapeutic benefits or induces untoward adverse events. Unfortunately, the seven years of market exclusivity awarded to orphan drugs manufacturers that garner regulatory approval for their products prohibits this. The biomanufacturing fiasco at Genzyme suggests that it may be time to reexamine the Orphan Drug Act and modify some of the financial and regulatory terms that were included to induce drug companies to develop new treatments for orphan disease indications.

Until next time…

Good Luck and Good Job Hunting!!!!!!!

 

Interviewing 101: "What Are Your Greatest Weaknesses?"

Over the course of a 30 year career and countless interviews, at one time or another I have been invariably asked: “What are your greatest weaknesses?”

The first time I was asked this question (1994) I almost said to the interviewer “Say what!!???!!!” Needless to say, the question took me totally by surprise and although I fumbled my way through the answer, I knew that I had blown it. A job offer never materialized.

The reason the question “through me for a loop” is because nobody had ever asked me that question while I worked in academia. After all, academics are taught to never reveal their weaknesses because that would be tantamount to admitting that they may be fallible which, in turn, may give others a reason to question their data…but I digress!

So, here is the bad news. For those of you seeking industrial and non-academic jobs, I guarantee that you will be asked the weakness question. Typically, it is delivered by Human Resources (HR) representatives who are asked to meet with job candidates during the interview process to go over things like salary, vacation time, benefits etc. However, based on my own experiences over the past few years, more and more non-HR folks seem to be asking the question.

Now, here is the good news; the question is not that difficult to answer if you think about it in advance and prepare a well thought out answer. The goal of the exercise is to identify (or create) a weakness that, if correctly crafted and presented the right way, can actually be perceived as a strength or positive personal trait.

During my “Interviewing Insights and Tips” seminar I usually give participants a few examples of strong weaknesses. Unfortunately, I’ve been using the same examples for the past five years or more and I think many HR professionals may be onto to my “answers. “ Consequently, I think it may be time for all of you smart and creative folks out there to come up with your own weakness.  To help with this, I recommend that you watch the following video.

Addendum: Never, ever tell an interviewer about a REAL or RECOGNIZED weakness, e.g., I don’t like interacting with people or I don’t like being told what to do. This will eliminate any possibility of a job offer. I know that the whole weakness thing may sound silly to many of you, but I can assure you that in the real world it may mean the difference between employment and living with your parents!

Until next time…

Good Luck and Good Job Hunting!!!!!!! 

 

BioJobBlog Surpasses the 1,000,000 Unique Visitors Mark

I started writing BioJobBlog about three years ago mainly to express my personal views on a variety of topics ranging from science education and career development to happenings in the pharmaceutical and biotechnology industries. At the time, blogging was a relatively new phenomenon (especially in the life sciences space) and I had no idea whether or not anybody would really care about what I thought or had to say. 

Apparently, some people do—last week the number of visitors to BioJobBlog quietly surpassed the 1,000,000 unique visitor mark. I say quietly because I had been assiduously watching my stats (like most bloggers) over the past few months to craft a post as soon as I surpassed the mark. Ironically, I inadvertently took my “eye off the ball” and unknowingly passed the mark earlier this week by about 15,000 page views. Go figure.

I want to thank everybody who reads BioJobBlog and finds my post useful. I know that at times I can be vitriolic and pedantic; but I am who I am and I guess you have to take the bad with the good—or not!

For those of you who may not know, BioJobBlog is self-funded (I have no sponsors or paid advertisers). Because of this, I get to say what I want, when I want and how I want to say it. Hopefully, my financial situation will remain stable so that I can continue to self finance the blog and “tell it the way it is” (or at least how I SEE it).

Finally, I want to thank the readers who send me comments and notes about my posts and the blog in general. Generally, they are helpful, incisive and thought provoking and provide fodder for new posts. With this in mind, if anyone is interested in appearing as a guest blogger at BioJobBlog, please don’t hesitate to contact me! While blogging is often fun and even addictive, it can become extremely tedious and  labor intensive at times.

Until next time…

Good Luck and Good Reading!!!!!!!!!!

 

What Prescription Drugs are in Your Future?

Reuters, the news service, published a list of prescription drugs that are predicted to likely to be the top sellers in 2014. For comparison purposes, the forecasts for the top sellers predicted for 2010 were also included.

 

Projected Sales 2010

   

Rank

Brand (Indication)

Company

Sales ($bln)

1

Lipitor (cholesterol)

Pfizer

              11.7

2

Plavix (clotting)

Sanofi Aventis

                9.6

3

Advair(asthma-COPD)

GSK

                9.0

4

Remicade (arthritis)

J&J

                7.4

5

Enbrel (arthritis)

Pfizer

                7.0

6

Humira (arthritis)

Abbott

                6.8

7

Avastin (cancer)

Roche

                6.7

8

Rituxan (cancer)

Roche

                6.1

9

Diovan (hypertension)

Novartis

                6.0

10

Crestor (cholesterol)

AstraZeneca

                5.8

       
 

Projected Sales 2014

 

Rank

Brand (Indication)

Company

Sales ($bln)

1

Avastin (cancer)

Roche

                8.9

2

Humira (arthritis)

Abbott

                8.5

3

Enbrel (arthritis)

Pfizer

                8.0

4

Crestor (cholesterol)

AstraZeneca

                7.7

5

Remicade (arthritis)

J&J

                7.6

6

Rituxan (cancer)

Roche

                7.4

7

Lantus (diabetes)

Sanofi Aventis

                7.1

8

Advair(asthma-COPD)

GSK

                6.8

9

Herceptin (cancer)

Roche

                6.4

10

Novolog (diabetes)

Novo Nordisk

                5.7

 

A quick perusal of the list suggests that there will likely be a shift toward the use of injected biologics in 2014 as compared with orally bioavailable small molecule drugs.

This should come as no surprise since most major pharmaceutical companies have publicly announced that biologics and biotechnology drugs are the key to their future successes.

Until next time

Good Luck and Good Job Hunting!!!!!

 

More Changes at Novartis

Earlier this year, Dan Vasella, the longtime CEO of the Swiss drug maker Novartis, announced that he was resigning his CEO position to assume a full time role as the Chairman of the company’s board of directors. Joe Jimenez, an American, was appointed as the new CEO.

Today, Novartis announced the departure of Ludwig Hanston, the CEO of the US pharma business unit for the past two years. In addition to his departure, four new business units will be formed and 250 employees will lose their jobs effective May 1, 2010.

The four new business units are being formed to more accurately reflect the needs of patient populations. The new business units include 1) Primary Care, 2) Multiple Sclerosis, 3) Psychiatry/Neuroscience and 4) Respiratory/Transplant/Infectious Disease.

For a more detailed explanation of the changes taking place at Novartis please read the post on today’s Pharmalot blog.

Hat tip to Ed.

Until next time…

Good Luck and Good Job Hunting!!!!!

 

The Dark Underside of New Jersey Dog Breeders Continued: More Info on Donna Roberts

Another BioJobBlog reader, who was previously burned on a puppy purchase, informed me of  another one of Donna Roberts’ puppy-selling scams. The information below was allegedly found on the American Kennel Club Online Breeder Classifieds under "Havanese"

 

Breeder Contact Information

Contact: DanaLyn Fitgerald

Location: SHAMONG, NJ 08088

Phone:

Email: mikimuppets@yahoo.com

In case you are wondering how Donna Roberts figures into the operation, DanaLyn (who lives in Barnegat, NJ) is another one of Donna Roberts’ daughters  who like her sister Dawn Abrams sells dogs on her mother’s behalf. 

While Donna's continued online ads are troubling, the fact that the American Kennel Club doesn't vet (so to speak) would-be advertisers on their classified ad sites is bothersome and unsettling.  If you can't trust what you find on the American Kennel Club's website, who can you trust when you want to purchase a healthy puppy?

Until next time…

Good Luck and Good Dog Hunting!!!!!!!!

 

Why Dogs Eat Grass

I have always wondered why dogs eat grass and other plants. After all there isn’t much nutritional value in them. An old wives tale or urban legend (more politically correct) suggests that dogs may eat grass because they are either sick or not feeling well. And, because of the grass eating they vomit afterwards to feel better.

It was just the other day that I asked my wife if she knew why dogs eat grass. Much to my surprise, the next day I came across an article in this month’s edition of the Healthy Pet Magazine that describes a study conducted by three veterinarians to find an answer to this vexing question. (Apparently, there isn’t even a consensus among veterinarians regarding the grass eating phenomenon).

The authors of the study conduct three surveys to get to the bottom of this conundrum. First they asked 25 veterinary students who owned dogs about their dogs’ grass eating habits. All reported that their dogs ate grass, didn’t exhibit an overt signs of illness and 8% said their dogs regularly vomited after afterwards

Next, they surveyed 47 dog owners that brought their dogs to veterinary hospital for outpatient care. Among this group, 70% per cent reported that their dogs ate plants mostly grass. Of the 37 owners that answered questions about their dog’s behavior before and after eating plants, 4 dogs showed signs of illness and only 6 vomited.

Finally, they conducted a web survey among dog owners whose dogs regularly eat plants or grass. Based on responses from 1,571 dog owners they found:

  • 68% of dogs ingested plants or grass on a daily or weekly basis
  • 8% of dogs frequently show signs of illness prior to eating plants or grass
  • 22% of dogs regularly vomit after eating plants
  • Of the plant eating dogs, younger dogs eat more than older dogs
  • There is no relationship between plant or grass eating and dietary habits (table scraps vs dog food) or fiber deficiencies

The bottom line: plant eating is a common behavior in normal dogs unrelated to illness and most dogs do not vomit afterwards. Vomiting seems to be incidental rather caused by plant eating.

This once again begs the question—why do dogs eat grass? The authors of the study posit that plant or grass eating may be a behavioral trait inherited from wolves (the dog’s ancestor) that may have possibly helped to purge the animals of parasites. In other words, nobody really knows the reason why dogs eat plants and grass.

Don’t you just love science? You get some answers to seemingly simple questions which, in turn, spawn new ideas and additional experimentation. I knew there had to be a reason why scientists decided to sequence the dog genome! Anybody up for finding the canine grass-eating gene(s)?

Until next time…

Good Luck and Good Job Hunting!!!!!!!!

 

Magic Mushrooms: Treating Cancer-Associated Depression

I came of age in the freewheeling 1960s and early 70s when the counterculture revolution was in full swing and people were regularly experimenting with marijuana and psychedelic drugs aka hallucinogens.

As a veteran of that era, I am well acquainted with these drugs and can personally tell you that they are not for everyone. However, the pharmacological active ingredients of marijuana (tetrahydrocannabinol) and the naturally-occurring hallucinogens found in peyote (mescaline) and magic mushrooms (psilocybin) have long been known to possess inherent therapeutic value. Unfortunately, because these drugs are associated with a particularly tumultuous period in American history, research into their use as therapeutic agents has long been stymied by the federal agencies that fund basic research in the US. 

Despite these formidable obstacles, a small number of intrepid researchers have managed to demonstrate that these long-vilified and illegal drugs can be used in some cases to treat cancer patients suffering from difficult-to-treat depression and other forms of mental illness. To that end, there was a fascinating article in yesterday’s New York Times that described a Johns Hopkins clinical study that showed that psilocybin can be used to manage untreatable depression in a small number of cancer patients.

The results from the study suggest that psilocybin, when administered using rigorous protocols and safeguards, can help to alleviate many of the symptoms of severe depression experienced by cancer patients undergoing chemotherapy. The researchers also contend that the use of hallucinogens can be transformative and may help to identify an endogenous neural pathway that may be responsible for so-called religious epiphanies.

Researchers from around the world are gathering this week in California for the largest conference on psychedelic science held in the United States in four decades. Attendees are expected to discuss studies of psilocybin and other psychoactive hallucinogens to treat depression in cancer patients, obsessive-compulsive disorder, end-of-life anxiety, post-traumatic stress disorder and addiction to drugs or alcohol.

Because reactions to hallucinogens can vary among individuals (primarily depending on the setting and external environment), researchers have developed stringent guidelines to set up a comfortable environment with expert monitors in the room to deal with adverse reactions. Also, they have established standard protocols so that the drugs’ effects can be assessed more accurately by scanning the brains of people who have taken hallucinogens. This is in marked contrast with the recreational use of hallucinogens which generally take place in a variety of sometimes difficult to control social settings; which may be responsible for some of the highly publicized “bad trips” experienced by hallucinogen users.

While there is no question that hallucinogens are very powerful psychoactive drugs—and their misuse can have serious cognitive and emotional consequences—it has never made sense to me why their use as potential therapeutic agents had been so discouraged. Ironically, marijuana and other illegal and so-called “dangerous illegal drugs” may actually be safer and more beneficial than some similar FDA-approved including certain antidepressants.

To be clear, I am not advocating the use of illegal drugs. However, in my experience, there is no obvious correlation between the legality of drugs and their potential therapeutic benefits. For example, both cigarettes and alcohol are legal drugs whereas marijuana (in many places) is not. A quick perusal of the number of people who are maimed or die each year from smoking pot as compared with those who die from lung cancer or are injured or killed by drunk drivers tends to emphasize this assertion. The bottom line: don’t throw any potential drug candidates on the pharmaceutical junk heap until they have been thoroughly researched and vetted as prospective therapeutic agents!

Until next time…

Good Luck and Good Job Hunting!!!!! (Right on man)

 

Internships: To Pay or Not to Pay Is the Question

There is a growing controversy over the rules governing whether internships offered by employers should be paid or unpaid. Many wage and hour regulators maintain that interns must be paid when their work is of “immediate advantage” to the employer. In this case, the interns should be considered employees and must be paid at least minimum wage. However, as the number of internships continues to rise, an increasing number of interns have complained of being placed in unpaid positions doing largely unskilled or menial work. Most labor experts agree that this provides an immediate financial advantage to an employer because the intern is doing unpaid work that is typically performed by a paid employee. 

Because of the growing popularity of internships, the federal government has established six criteria to determine whether or not internships can be unpaid. These include that the internship must resemble instruction or training given in a vocational skill or academic institution and that the intern does not displace or replace a paid employee and that the employer does not gain an immediate advantage from the intern’s work and activities. In other words, if an intern’s experience is mainly educational or beneficial to the intern the internship does not have to be a paid one. To confound the issue, the California labor department recently issued new guidelines on whether or not internships should be paid, with the new rules giving employers more latitude not to pay them

According to a recent article in the New York Times, the new rules stipulate that interns need not always be paid when they do some of the same work as company employees. The new guidelines suggest that interns could do occasional work done by regular employees as long as it “does not unreasonably replace or impede the education objective for the intern and effectively displace regular workers.” I suspect that other states will follow suit and redefine their criteria for unpaid internships.

Don’t be surprised if you see a spike in the number of unpaid internships offered for the summer of 2010 and beyond.

Until next time…

Good Luck and Good Job Hunting!!!

 

Job Seekers: Your Credit Score May Be More Important Than You Think

There was a troubling article in this past Saturday’s New York Times that revealed that an increasing number of employers are using job applicants’ credit scores to determine whether or not to hire them. Persons with poor or lower credit scores are assumed to be less reliable and trustworthy employees (despite experience and skill sets) as compared with those with good credit scores. Interestingly, while many would be employers subscribe to this notion, there are no data whatsoever to support the claim! In other words, there is no scientific or statistical evidence showing that people with weak credit are more likely than those with good credit to be bad employees or steal from their employers. Because of the recession, many people’s credit scores have been adversely affected. This has prompted legislators in 13 states to introduce bills to limit the use of credits reports as a factor in the hiring process. To date, three states have passed such laws.

Supporters of these laws contend that the use of credit checks to screen prospective employers unfairly targets a huge pool of individuals whose credit was damaged by layoffs, medical bills or other factors beyond their control. This caused one Connecticut legislator, who recently introduced legislation to curb the use of credit checks by employers to quip “Bernie Madoff had a pretty good credit score. And yet there is this consistent message that if you have a bad credit score, there is something wrong with you.” Finally, and perhaps most egregiously, the practice tends to disproportionately screen out prospective minority employees. 

Not surprisingly, companies that sell credit checks (Experian, TransUnion, etc) have mounted a vigorous lobbying campaign against any legislation limiting the use of credit check by employers in the hiring process. These lobbyists contend that preventing the use of credit checks could seriously jeopardize a company’s assets, reputation or security.

A survey released earlier this year by the Society for Human Resources Management revealed that 13 percent of employers used credit checks on all job applicants whereas 47 percent say they use credit checks for certain applicants. Among those surveyed, 54 percent said they use credit checks on prospective employees to prevent theft and embezzlement. Ninety0one percent they used credit checks for job applicants seeking positions with fiduciary or financial responsibility. Most of the proposed bills to curb the use of credit checks allow them to be used for positions that involve the handling of money or confidential and proprietary information.

Unfortunately, in the current economy, employers are looking for any excuse to not hire certain job applicants. In my opinion, the growing use credit scores to screen job applicants is offensive and demeaning and should not be a determining factor (unless handling money is involved) in the hiring process. It is an overtly discriminatory practice that can seriously impede hardworking people from securing gainful employment to provide for themselves and their families. Kudos to the legislators who possess the moral and ethical convictions to propose legislation that protects the rights of jobseekers who simply want to make a living.

In case you are wondering, my credit score is in the mid 750s. Conventional wisdom suggests that scores below 600 may be dicey. With this in mind, I highly recommend that you check your credit score before you go on your next job interview—it may give you some insight into whether or not to expect a job offer.

Until next time…

Good Luck and Good Job Hunting!!!!!!

 

A Day in the Life at a Genome Engineering Company

Cellectics, SA, a French genomic engineering and genetic surgery company is a great example of a biotechnology company that “gets” social media. 

The person, who manages the company’s Twitter account, posted a video on YouTube called a “ A Day at Cellectics. While not quite Avatar, it is short, fun to watch and if nothing else, it shows prospective employees that Cellectics may be a cool place to work! 

While I can’t vouch for Cellectics’ science, it is a company that knows how to leverage social media for better business outcomes! 

Until next time…

 

Good Luck and Good Tweeting!!!!

 

Women in Science

In March 2009, the Smithsonian Institution Archives (SIA) created a photography exhibit to honor women in science and engineering. The exhibit consists of photographs of famous and not-so-famous female scientists, a brief bio and description of their work.

Many of the photographs are from the 1920s and 1930s when female scientists were a rarity. Fortunately, this has changed in recent years and more women than men are currently enrolled in graduate programs in the life sciences. To learn more, you can visit the SIA blog.

The exhibit is interesting and worth a look!

Hap tip to Julian for sending me the link.

Until next time…

Good Luck and Good Job Hunting!!!!!!

 

Dawn Abrams and Donna Roberts Continue to Scam Would Be Dog Owners

Despite court rulings, statewide investigations and public humiliation, Dawn Abrams and Donna Roberts continue to scam would be dog owners who want to buy puppies and give them good homes. 

A would be client sent me an e-mail message claiming that he was duped by the dynamic duo of sleaze because he didn’t research them in advance. Like me, he believed that these people were legitimate before it was too late. 

According to his message, these brazen and seemingly unrelenting grifters are currently doing business as:

Havanese Puppies Ready to Go (Danalyn, Medford/Vincentown)

537 Oakshade Rd., Vincentown, NJ 08008

609-346-6571

The Vincentown address is where Dawn Roberts lives in a run down farm house with 6 children. Apparently, Donna Roberts is using one of her tried and true aliases Marie Dueben (who I think is the name of one of her ex-husband’s wives). The person who wrote to me contends that these odious individuals are also doing business as My Cute Muppets on the Puppyfind website.

Despite repeated unsuccessful attempts to shut Dawn and Donna down, these amoral and unethical scumbags continue to dupe innocent, unsuspecting would-be dog owners. It is a shame that these jerks are not big enough criminals to make it onto the New Jersey State radar of people to put away. But, as I always say, what goes around comes around.

And I hope that Dawn and Donna’s days of reckoning comes around sooner rather than later.

Until next time…

Keep the faith; there is justice in the world! 

 

Ranbaxy to Hire 1,500 Marketing and Sales Employees to Boldly Go Where No Indian Pharmaceutical Company Has Gone Before

One economic downturn and it seems as though the pharmaceutical world has been turned upside down! Who would have thought a few years ago that emerging pharmaceutical markets in India and Asia will outpace the US and Western European markets in the very near future (I did but nobody listens to me). To that end, Ranbaxy Laboratories will hire nearly 1,500 marketing executives, expanding its sales team by at least 50%, to spur sales and regain its rank as India’s top drug maker. The recruitment push is among the biggest by an Indian drug maker in recent years.  Ironically, pharma sales reps are still being regularly layed off in the US.

The company plans to hire mostly medical representatives, regional managers and area managers by July to boost sales in the rural markets.  According to a Ranbaxy hiring manager “Ranbaxy is looking at new rural markets and deeper penetration in interior markets.”

Ranbaxy is owned by Japan’s Daiichi Sankyo which employs over 12,000 people in 46 countries.

Industry analysts suggest that Ranbaxy’s aggressive hiring push is a sign that the company is focusing on internal markets which are poised for exponential growth in the next few years. Also, Ranbaxy has had its share of legal and regulatory disputes over patents and generics drugs in the US and Western Europe signaling that the company may be pursuing those markets less aggressively than in the past.

Until next time…

Good Luck and Good Job Hunting!!!!!!!

 

The Downsizing Continues: Sanofi-Aventis Lays Off 400 Workers

According to a post on Pharmalot, a great blog run by the intrepid Ed Silverman, Sanofi-Aventis is laying off 400 employees; most of the them sales representative. The layoffs are in response to impending generic competition for several of the company’s older medications— the Ambien CR sleeping pill and Aplenzin antidepressant and declining sales of Actonel an osteoporosis medication. And, based on statements made by a company executive who manages the company’s therapeutic portfolio this may only be the tip of the iceberg as revenues from brand drugs continue to decline over the next few years.

Until next time..

Good Luck and Good Job Hunting!!!!!

 

Social Media and Microbiology

Virologist and BioCrowd co-founder Vincent Racaniello, PhD recently gave a talk at the Spring 2010 meeting of the Society for General Microbiology in Edinburgh, Scotland.

The talk, entitled ‘Social Media in Microbiology Education and Research’ reviewed how Professor Racaniello uses blogging, podcasting, and other social media tools to teach the public about viruses.

To learn more about Vincent and how he uses social media to increase the publics’ awareness about viruses and other infectious agents, please visit the BioCrowd website.

Until next time…

Good Luck and Good Job Hunting!!!!!!!!!

 

Biocareer Development: The Truth About Internships

The recent economic downturn, coupled with the growing competition for jobs at pharmaceutical and biotechnology companies, has markedly increased the importance of internships as pre-requisites to gainful permanent employment. In the past, life sciences companies were willing to take a risk on promising new employees who did not possess any previous work experience. However, the glut of life scientists on today’s job market has empowered prospective life science employers to adopt a “let’s-try-them-out-before-we-hire-them” approach to employment. Like it or not, this is the way business is done these days.

While many life sciences companies continue to compensate their interns, an article in this past Saturday’s New York Times suggested that there is a growing number of organizations that are failing to pay their interns. This has caused federal and state regulators to worry that more employers are illegally using such internships for free labor. Many regulators say that violations are widespread, but that it is unusually hard to mount a major enforcement effort because interns are often afraid to file complaints. Many fear they will become known as troublemakers in their chosen field, endangering their chances with a potential future employer.

According to the article, in 2008, the National Association of Colleges and Employers found that 83 percent of graduating students had held internships, up from 9 percent in 1992. This means hundreds of thousands of students hold internships each year; some experts estimate that one-fourth to one-half are unpaid. Further, there are data to suggest that unpaid internships have been skyrocketing in recent years; mainly fueled by employers’ desire to hold down costs and students’ eagerness to gain experience for their résumés. For example, a career development expert at Stanford University noted that “employers posted 643 unpaid internships on Stanford’s job board this academic year, more than triple the 174 posted two years ago.” Other universities report similar trends.

While the primary goal of internships is to educate and prepare students for future jobs in their chosen fields of endeavor, some employers tend to view even paid interns as free labor and: asking them to do perform unskilled, menial tasks rather than pay hourly workers to perform them. Nevertheless, there is no question that spending a summer or semester as an intern at a life sciences company seriously increases the likelihood of permanent employment (either at that company or one of its competitors). After all, the internship experience (whether or not you performed any relevant work) qualifies as previous industrial experience. And, as many recent jobseekers will tell you, “previous industrial experience” is an absolute requirement these days to land a permanent job at a life sciences company. 

In the past, I unabashedly recommended that students who want to land jobs at life sciences companies consider taking an unpaid internship if a paid one wasn’t possible. However, I am no longer certain that this approach may continue to be viable or valuable one. To that end, working as an unpaid, life sciences intern taking lunch orders, fetching coffee, copying journal articles or conducting PubMed sources for the VP of R&D may not be helpful to you or a prospective new employer.  With this in mind, I suggest that before agreeing to a life science internship (paid or otherwise) that you ask for a job description and a list of your responsibilities and functions. If a company is unwilling or unable to provide you with this information, I highly recommend that you move on to the next possibility. After all, nothing is life is free!

Until next time….

Good Luck and Good Job Hunting!!!!!!!!

 

US Sale of Prescription Drugs Tops $300 Billion in 2009

IMS Health, a market intelligence company that tracks US drug prescriptions, reported that the US sale of prescription drugs grew 5.1% in 2009 to $300.3 billion.

IMS identified the following key trends among the major therapeutic areas:

  • Antipsychotics remained the top-selling class of medications in the U.S., with 2009 prescription sales of $14.6 billion, equal to the 2008 level.
  • Lipid regulators continued as the largest therapy class in the U.S. by dispensed prescription volume, growing at a 5 percent pace to 212 million prescriptions dispensed in 2009. Sales of lipid regulators declined 10 percent last year to $13.1 billion, reflecting an ongoing shift toward lower-cost generic alternatives. Lipid regulators ranked #3 in overall sales in 2009.
  • Proton pump inhibitors replaced lipid regulators as the second-largest therapeutic class in sales last year. Proton pump inhibitors sales totaled $13.6 billion, a 2 percent decline year over year, while dispensed prescription volume for this therapeutic class rose 5 percent.
  • Antidepressants became the fourth-largest class in 2009, up from its #5 ranking the prior year, with U.S. prescription sales growth of 3 percent to $9.9 billion.
  • Sales of antineoplastic monoclonal antibodies, a leading oncology class that includes Avastin®, Rituxan® and Herceptin®, grew at a 9 percent pace in 2009 and ranked #6 in therapeutic class sales.

IMS also reported that use of generic products, including branded generics, continued to rise last year and now represent 75 percent of all dispensed prescriptions in the U.S., up from 57 percent in 2004. The total number of generic prescriptions dispensed increased 5.9 percent in 2009, while the number of branded prescriptions dispensed declined 7.6 percent.

While the US pharmaceutical and biotechnology industries continue to cry poverty, it appears that sale of prescriptions drugs continues to grow at a pretty good rate. Look for increased growth until 2014 when healthcare reform begins to kick in.

Until next time…

Good Luck and Good Job Hunting!!!!!!!

 

Pharma Layoffs Continue Unabated

Pfizer today announced that it would lay off another 123 workers at its Pearl River, NY manufacturing and R&D site.

The workers in the facility's research and development division will lose their jobs by early July according to a company spokesperson. He added "There may be some additional positions eliminated over the course of 2010, but this is the last major wave that will be announced.”

This brings to 601 the total number of layoffs at the site. The cuts are part of a global restructuring Pfizer announced in November, weeks after acquiring Wyeth Pharmaceuticals. The company has yet to decide the fate of the plant's manufacturing arm. If it is shuttered, that could lead to more layoffs

In other news, lesser known KV Pharma said it would shed 289 workers or 42 percent of its workforce. KV already had reduced its staff from 1,700 in 2008 to about 680 as of Feb. 28. The company recently shut down its generics subsidiary Ethex Corp. after the company pleaded guilty to criminal charges for not disclosing problems with two of its drugs and agreed to pay $27.6 million in fines and restitution.

While the US government and financial analysts claim that the economy is show signs of improvement, the layoffs at pharma and biotech companies continue. Only time will tell if we have truly turned a corner during this economic downturn.

Hat tip to the Pharmalot blog!

Until next time...

Good Luck and Good Job Hunting!!!!!!!!